Video

Dr. Yardley Discusses Enzalutamide in HR+ Breast Cancer

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the randomized placebo-controlled phase II trial evaluating exemestane with/without enzalutamide (Xtandi) in patients with hormone receptor (HR)-positive breast cancer

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the randomized placebo-controlled phase II trial evaluating exemestane with/without enzalutamide (Xtandi) in patients with hormone receptor (HR)-positive breast cancer

The androgen receptor is prevalent in 30% of patients with triple-negative breast cancer (TNBC). The androgen receptor is expressed in 80% to 90% in patients with HR-positive breast cancer. According to Yardley, this could be a target for the management of endocrine-positive breast cancer.

This trial had 2 cohorts. The first cohort had no prior endocrine therapy whereas the other had one prior therapy for patients with advanced disease. With a biomarker evaluation, this study predicted a group that was sensitive to enzalutamide and demonstrated progression-free survival, explains Yardley.

Related Videos
J. Bradley Elder, MD
Rimas V. Lukas, MD
Shubham Pant, MD, MBBS
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD